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Summary The biochemical effects of CHIP have been studied in C3H mice with and without transplanted
mammary tumour. The maximum tolerated dose of CHIP was first determined by lethality and intestinal
crypt assays to be 40mgkg-' and this dose was used to assay the time course of gastric distension and the
pattern of drug distribution. A high level of CHIP uptake was found in liver as well as kidney. For this
reason, tests for both kidney and liver damage were undertaken up to 60 days post-treatment using a dose of
10mgkg-1 Neoplatin for comparison. Despite the high level of platinum drug uptake in liver, there was no
biochemical evidence of hepatocellular or cholestatic damage. From the renal point of view, there was the
expected rise in serum urea after Neoplatin but not after CHIP and there was also a rise in urinary NAG
after Neoplatin in tumour bearing mice. There was, however, evidence of suppression of protein levels
including enzymes, following treatment with both drugs. Tumour-bearing mice respond differently from
normal mice following treatment with platinum drugs. The study confirms that CHIP is less toxic than
Neoplatin.
The aim of this paper is to show that precise data
can be obtained on the biochemical effects of
cancer chemotherapy in experimental animals, and
that this should include tumour-bearing animals.
This is of particular importance since mouse and
other small rodent data are often put forward as
the main basis for a Phase I clinical trial. Neoplatin
(cis dichlorodiammine platinum II) is a first
generation platinum anticancer drug, and the
activity and biochemical effects in humans have
been well documented from clinical trials (Dentino
et al., 1976; Wiltshaw, 1978). CHIP (cis dichloro
trans-dihydroxy bis isopropylamine platinum IV), is
a more soluble platinum complex, selected as a
second generation drug (Shepherd et al., 1980) in
the hope that it will be at least as effective an
antitumour agent as Neoplatin, will have reduced
toxic side effects (especially nephrotoxicity and
nausea) and will not exhibit cross resistance with
Neoplatin resistant tumours. CHIP is now in
clinical trial (Creaven et al., 1983).
In the experiments reported here, the maximum
tolerated dose of Chip was first estimated from
LDSO experiments and the gastrointestinal toxicity
confirmed using assays of intestinal crypt damage
and gastric distension. The distribution of CHIP in
the mouse tissues was shown by radioactive
platinum labelled CHIP incorporation and this
confirmed the high levels of platinum drug in the
liver and kidney.
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The biochemical tests which have been used for
analysis were selected because, in our experience,
they were of particular importance in assessing
biochemical changes in human disease. Haemato-
logical analysis is also routinely carried out and is
of paramount importance in the assessment of
platinum drug toxicity. However, in this paper we
are concerned primarily with the detection and
effects of renal and liver toxicity.
The values obtained for the various biochemical
parameters after treatment with CHIP have been
compared, both with those of age and sex matched
untreated tumour and nontumour bearing mice,
and also with similar mice treated with Neoplatin.
Materials and methods
Animals
Male and female SPF derived C3H/He/GB-
Sth(2SMq) mice, aged between 10 and 14 weeks
were used in all experiments (mouse weights ranged
from 25-30g).
The tumour-bearing mice had been implanted in
the dorsal region with C3H mouse mammary
carcinoma (as described in Tozer et al., 1984). They
were treated when the tumour measured between 6-
8mm diameter.
Drugs
CHIP and Neoplatin were supplied by Johnson
Matthey Ltd. Stock solutions in saline were
prepared freshly for each experiment. Sagatal
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(pentobarbitone sodium 60mgml-1) was supplied
by May and Baker Ltd, Dagenham.
CHIP toxicity
Acute toxicity from CHIP in the mouse is manifest
as the gastro-intestinal syndrome. This was assayed
in terms of reduction in the number of regenerating
crypts of lieberkuhn in the jejunum using the
method of Withers and Elkind (1970) but with the
assay at 5 days because of the slower kinetics in
SPF mice. Gastric distension was measured by
stomach volume and lethality. Except for the first
seven hours the volumes were assayed in the
afternoon of each day.
Distribution studies ofradioactive CHIP
Two isotopes of Platinum were used. 191Platinum is
a gamma emitter suitable only for scintillation
counting. 19lmPlatinum is a gamma emitter which
also emits high energy conversion electrons which
are similar to beta particles. It is therefore possible
to perform crude autoradiography as well as
scintillation counting of labelled tissues with that
isotope. 191Pt-CHIP was kindly supplied by Dr H.
Sharma of Manchester University (Sharma and
Smith, 1981) and 195mPt-CHIP was kindly supplied
by Dr J.D. Hoeschele of Oak Ridge National
Laboratory, Tennessee (Hoeschele et al., 1984).
Tumour-bearing mice were given one or the other
of the isotopes at a CHIP dosage of 40mgkg-1
and sacrificed at the following times after
intraperitoneal injection: 15 and 30min, 1, 2, 4, 6,
8, 12, 24 and 48h. Urine, blood, tumour, kidney,
liver and small intestine were then removed for
scintillation counting in the case of both isotopes.
Sample collection
(a) Short period A group of 50 male and 50
female mice (age 12 weeks) were randomised, with
respect to weight, into 5 groups of 10 males and 10
females. Each animal was given a single i.p. dose of
either CHIP (40mgkg-1) or Neoplatin
(10mgkg-1). Urine and serum were collected from
separate groups of mice on days 4, 7, 9, 11, 14 after
drug treatment. The animals were sacrificed by the
administration of a lethal dose of Sagatal (3mg in
0.05ml). The method of collection and processing
these samples has been described elsewhere (Kind et
al., 1985).
(b) Long period Fifty males and 50 females (age
12 weeks) were randomised and treated according
to the method of the short term study. Urine and
serum collections were made on days 0 (treatment
day) 20, 30, 45, 60 after treatment (animals were
aged 20 weeks by day 60 of the experiment).
(c) Tumour-bearing C3H mice (50 male and 50
female between 12-15 weeks old) were transplanted
with C3H/H mouse mammary tumour as described
elsewhere (Kind et al., 1985). When the tumours
were palpable (usually 7 days later) the mice were
given a single i.p. dose of either CHIP (40mgkg-1)
or Neoplatin (10mgkg-1). Urine and serum were
collected, from groups of 10 males and 10 females
as before on days 1, 4, 9, 11 after treatment. These
mice could not be investigated for a longer period,
because they had to be sacrificed when the tumour
had grown beyond an acceptable size. During that
period there was no significant loss in the net
weight of untreated tumour-bearing mice (i.e. after
correction for tumour weight).
Biochemical techniques
For the analytical methods used, methods of blood
and urine collection and relevant age matched
reference ranges for normal and tumour-bearing
mice see Kind et al. (1985). These values provided
the control data.
For the assessment of hepatotoxicity, the serum
levels of alkaline phosphatase (AP), and of
aspartate transaminase (AsT) and alanine trans-
aminases (AlT) were chosen. Nephrotoxicity was
assessed by the serum urea and creatinine levels,
and also urinary protein and a urinary enzyme of
proximal renal tubular origin, N-acetyl-fl-D
glucosaminidase (NAG), known to be a sensitive
indicator of renal tubular damage. The urine values
have been related to creatinine excretion as timed
urine collections were impractical.
Results
Determination ofmaximum dose (MTD) ofCHIP
Figure 1 shows the response of male mice to single
doses of CHIP. After an initial threshold there is an
exponential dose response (Do 12.5mgkg-1) in
terms of the reduction in regenerating crypts of
lieberkuhn assayed in transverse sections ofjejunum
examined 5 days after treatment. (A similar result
was obtained with female mice, Do 12mgkg-1).
This assay measures drug toxicity to the intestinal
epithelial cell population. These data together with
the results of an LDSO experiment (LD50
65mgkg-1) lead to the conclusion that 40mgkg-1
of CHIP could be considered to be the maximum
tolerated dose for biochemical and drug
distribution studies.
Since nausea and vomiting are important side
effects of platinum chemotherapy, the effect of a
MTD upon the stomach was also evaluated.
Although emesis does not occur in mice, severeBIOCHEMICAL EFFECTS OF CHIP IN MICE 763
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gastric distension does. As part of an earlier study
(Jones & Stone, 1983), the weights and volumes of
stomachs were measured at intervals after the
administration of maximum tolerated doses of
CHIP or Neoplatin. After both drugs there was an
increase in stomach weight and volume above
controls. The volume data for animals treated with
CHIP are shown in Figure 2 (previously
unpublished). Distension started at 7h and reached
a peak at 24h after injection of CHIP. The volume
then returned to within normal limits from 4 days
onwards. The total weight of the treated animals
was only slightly reduced at 4 days and had
returned to the control value by 14 days.
Biodistribution ofCHIP
Figure 3 shows the scintillation counts obtainied
with a MTD of CHIP labelled with '91Pt. The
levels of activity were much higher in liver and
kidney than in intestine and tumour. The levels for
125 all the three normal tissues fell rapidly during the
first 4h and there was then a plateau for the next
8h before a further fall. By contrast, the level in
rypts of tumour rose to a maximum at 6h and this was then
er CHIP maintained for the next 6h before falling. The urine
levels (not shown) started at a very high level but
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Figure 2 Time course of gastric distension after a maximum tolerated dose of CHIP (0) measured as the
increase in stomach volume (cm3) and compared with stomachs of control mice (0). Values are the mean
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Figure 3 Incorporation of Ptl9l-CHIP into kidney (x), liver (A) intestine (0) and tumour (0) of male
mice after a single dose of40mgkg-1 CHIP191. Values are the mean +s.e.
fell to similar levels to kidney and liver from 12h
onwards. The blood levels (not shown) were in the
same lower range as intestine and tumour. Similar
data were obtained with CHIP labelled with
1955mPt
Biochemical changes
Serum aspartate and alanine transaminases (AsT and
AlT) Neither CHIP nor Neoplatin appeared to
have any effect on the levels of enzyme activity
which remained within the normal range
throughout the period of investigation in both non-
tumour-bearing and tumour-bearing mice.
Serum alkaline phosphatase (AP) Figure 4 shows
the level of AP in serum from normal untreated
mice (male and female) at different ages and from
tumour-bearing mice aged 15 weeks obtained from
our control studies (Kind et al., 1985). There was
an initial fall in enzyme levels in female mice aged
between 10 and 20 weeks and in male mice aged
between 10 and 25 weeks after which the levels
plateau, while the tumour-bearing mice, aged 15
weeks, show a much lower level of enzyme activity.
Short and long term changes in AP levels have
been plotted on different figures in order to take
account of the relative ages of the mice. Figure 5
(a) gives the results for the short term study andBIOCHEMICAL EFFECTS OF CHIP IN MICE 765
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Figure 4 Age relationship of serum alkaline phosphatase levels (i.u. I-1, mean +1 s.d.) in untreated non-
tumour-bearing female (0) and male (x) mice and untreated tumour-bearing female (E) and male (A) mice.
shows AP in female normal and tumour-bearing
mice after treatment with either CHIP or Neoplatin
and related to the age of the mice on the day of
collection. (The days post treatment are given in
parenthesis). In non-tumour bearing mice there
appears to be a drop in the level of AP at day 9
after treatment with CHIP which then reaches a
plateau. In Neoplatin treated mice the AP was
significantly lower than the control values and also
than the AP in CHIP treated animals, with a sharp
fall on day 7 and then a rise but never returning to
within the normal range.
This is confirmed in Figure 5 (b) which gives the
results for the long term study and shows the AP in
female mice on days 0, 20, 30, 45 and 60 and
related to mouse age. Enzyme activity with CHIP
and Neoplatin treated mice remained significantly
below the normal range and continued to fall as the
age of the mice increased in a similar manner to the
normal untreated mice. There was no significant
difference between the levels found in CHIP or
Neoplatin treated mice. Male mice showed a similar
depression in AP after drug treatment.
From the data for untreated mice given in Figure
4 it can be seen that the levels of AP were
depressed in tumour-bearing mice as compared with
the non-tumour-bearing mice; however after treat-
ment, although the enzyme activity had a lower
starting level, the pattern of depression of AP
activity was similar (Figure 5a). Long term studies
were not available as it was impossible to do these
on the tumour-bearing mice.
Serum lipids Tumour-bearing mice developed
marked lipaemia 'following CHIP treatment.
However this was not detected in non-tumour-
bearing or Neoplatin treated mice. Serum try-
glycerides rose to eight times normal level
appearing on Day 1 after CHIP treatment, reaching
a maximum at Day 4, then decreasing slowly but
still present after 15 days when the mice were
sacrificed.
Serum urea and creatinine The effect of CHIP and
Neoplatin on the serum urea and creatinine levels
in normal and tumour-bearing male mice are shown
in Figure 6. The serum urea levels showed a
significant elevation after Neoplatin treatment in
both normal and tumour-bearing mice. This rise
was maintained and possibly increased up to the 60
days post treatment. There was no corresponding
rise in the serum creatinine, in fact, the levels were
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Figure 5 Age relationship of serum alkaline phosphatase levels mean +±1 s.d. in female non-tumour-bearing
mice treated with a single dose of Neoplatin (10mgkg-(Q)) or CHIP (40mgkg- (A)). Closed symbols
show data for tumour-bearing animals. Serum was collected from I group of 10 animals sacrificed on each
collection day (Day Number given in parenthesis) (a) over a Short Period post treatment (4-14 days) (b) over
a Long Period post treatment (0-60 days). Control levels for untreated normal female mice were included for
comparison ([1).
slightly depressed at Day 7 post treatment (Day 9
in tumour-bearing mice) and then rose slightly.
In CHIP treated mice the serum urea levels only
showed a slight increase around day 45 but then
returned to within the normal range. On days 4 and
9 the serum creatinine was elevated. In the tumour-
bearing mice on Day 1 post treatment there was an
elevation in urea and creatinine above the normal
range, but this soon returned to normal. A similar
pattern was observed from the female mice.
Urinary protein and N-acetyl-f3-D-glucosaminidase
(NAG) related to creatinine levels Both urinary
protein and urinary NAG levels were estimated and
related to urinary creatinine levels in drug treated
mice. The results for male mice are shown in Figure
7. After both drugs the levels of urinary protein
were depressed well below the normal range and
remained so throughout the period of investigation
and this also applied to the level of urinary NAG
in Neoplatin treated mice. In CHIP treated mice
the NAG level appeared to remain normal for the
first 20 days but then dropped sharply to a low
level similar to that measured in the Neoplatin
treated mice.
In the tumour-bearing mice the pattern is not so
clear. There appears to be no depression below the
control level established for the mice (Kind et al.,
1985) of urinary protein after either drug. After
Neoplatin treatment, there was an initial rise in the
level of urinary NAG and after CHIP treatment
there was an initial fall but these levels soon
returned to within the control ranges. A similar
pattern was observed in female mice.
Discussion
In any study of the toxic effects of chemothera-
peutic agents in vivo, it is important to choose a
drug dose which would be likely to elicit a response
similar to that expected in a human patient. For
example, if too high a drug dose is used, the toxic
changes observed may only be those preliminary to
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Figure 6 Response of serum urea levels and serum creatinine levels in non-tumour-bearing and tumour-
bearing male mice to treatment with a single dose of either Neoplatin (lOmgkg-' (0)) or CHIP
(40mgkg-1(A)). The control reference ranges (-- ) are taken from 10-20 week old mice. All values are
mean + I s.d.
the death or severe incapacitation of the animal and
are therefore not relevant to the clinical situation.
The maximum tolerated dose (MTD) is a dose level
which is routinely accepted as valid in the
comparison and evaluation of different drugs in
vivo. The MTD is defined as the largest dose where
no deaths occur and the animal looks quite normal
and healthy (i.e. no large weight loss etc).
The MTD of 40 mgkg-I CHIP was estimated
from lethality studies and confirmed further by the
use of the microcolony technique (Withers &
Elkind, 1970). This is an assay which measures the
percentage of crypts of lieberkuhn in the small
intestine which are able to regenerate after
increasing single doses of CHIP. This technique was
developed to provide an assay of the cytotoxic
effect of ionizing radiation on intestinal epithelial
stem cells. Mice irradiated with large doses die of a
gastro-intestinal syndrome which can be directly
correlated with this cytotoxic effect on intestinal
stem cells. The LD50 dose of radiation is 13 Gy
in mice and this is a dose level at which only 50%
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Figure 7 Levels of urinary protein and urinary NAG related to creatinine after treatment of male mice with
a single dose of either Neoplatin (IOmgkg-I (O)) or CHIP (40mgkg (/A)). The control reference ranges
(---) are for 10 20 week old mice. All values are mean ± I s.d.
of the crypts of lieberkuhn are able to regenerate
(Hamlet et al., 1976). This technique is particularly
relevant to the assessment of platinum drug toxicity
where the mice also die of gastrointestinal toxicity.
Therefore, the intestinal epithelium is a prime target
for this drug. As can be seen in Figure 1, the MTD
of 40mgkg-1 CHIP allows 99% of crypts to
regenerate, whereas the LD50 dose of 65mgkg-
permits only 50% of the crypts to regenerate.
The gastrointestinal toxicity had previously been
studied by the measurement of gastric distension
after drug treatment (Jones & Stone, 1983). This
distension is believed to indicate gastric toxicity in
animals which do not show symptoms of nausea
and vomiting. It can be seen from Figure 2 that
even at the MTD CHIP induces a marked gastric
distension commencing at 7h after drug
treatment, reaching a maximum at 24h and
gradually returning to normal at about 4 days post
treatment. The stomach volume remained within
normal limits during the remainder of the fourteen
days after treatment as did the weight of the
animals. The biochemical changes from four days
onward are therefore likely to be due to other
causes.
Biodistribution ofCHIP
The biodistribution of CHIP has been studied by
Hoeschele et al. (1984) using 195mPt labelled drugBIOCHEMICAL EFFECTS OF CHIP IN MICE 769
administered to normal female rats. They found the
same sort of biphasic pattern as was found for the
mice in Figure 3, with an initially rapid decline in
radioactivity and then a much slower decline.
Thatcher et al. (1982) compared the clearance of
191Pt labelled Neoplatin and CHIP from a small
series of patients with malignant disease and also
found a biphasic pattern of blood clearance which
was the same for both drugs. On the other hand,
the urinary excretion was greater for CHIP than for
Neoplatin. They concluded that this difference
might indicate that CHIP is potentially less
nephrotoxic than Neoplatin.
Hoeschele et al. (1984) had compared the radio-
activity in a number of rat tissues and found a
much higher level in kidney than in other normal
tissues, but in their rats the level in liver was
intermediate unlike the high level shown in the mice
in Figure 3. They noted that the level of CHIP in
liver was twice as high as that of Neoplatin at 24h
after injection. Hepatotoxicity as well as nephro-
toxicity might therefore have been expected after
CHIP treatment. This was why the present study
includes biochemical assays of both kidney and
liver damage over a 60-day period, this allowing
time for the damage after a MTD to become
manifest in these organs where the cell populations
have much slower kinetics than in the intestine.
The initially high level in the small intestine
(Figure 3) would account for the intestinal toxicity
manifest in the crypts of lieberkuhn (Figure 1) and
the early onset of lethality when higher drug dosage
was used.
Hoeschele et al. (1964) studied normal rats
whereas the data in Figure 3 apply to tumour-
bearing mice. The uptake of CHIP into the tumour
eventually rose to the same level as found in the
small intestine and the blood. This confirms the
potential of CHIP for cancer chemotherapy and
also as a radiosensitizing agent (Laverick & Nias,
1981).
From the initial toxicity data and radioactive
incorporation of platinum, it can be seen that the
liver and kidney are organs which may be prime
targets for the two platinum drugs when used at a
non-lethal dose level. Therefore, renal function and
liver function were analysed in greater detail using
the biochemical tests described after the treatment
of the mice with a single MTD of either drug.
Hepatotoxicity
There are no reports of liver damage from platinum
drug administration but equally high concentrations
of CHIP were found in the liver as in the kidney.
Hence appropriate enzyme assays were performed
to assess liver involvement.
Serum transaminase activity The marked differences
seen in levels of serum transaminase for non-
tumour bearing and tumour-bearing mice have
already been reported (Kind et al., 1985). The
higher AsT level found in the tumour bearing mice
(when compared with non-tumour bearing mice of
the same age) could be consistent with some degree
of hepatotoxicity as in humans. This could be the
result of damage to hepatocytes, the enzymes
leaking out from the cell either due to changed
permeability or due to cell necrosis. It could be
postulated that the absence of any change in
transaminase levels in the drug treated tumour and
non-tumour-bearing mice may not therefore
necessarily exclude some toxic effect of platinum as
suppression of protein synthesis is known to occur
with this drug, thus masking any rise due to
toxicity. The platinum complexes bind avidly to
proteins, and they are known to slow down the rate
at which cells pass through the cell cycle and cause
delay of cells entering into mitosis or at the Gl/S
boundary of the cell cycle (Szumiel & Nias, 1976;
Barot et al., 1985). This could well be a direct or
indirect effect of altered intracellular enzyme levels.
Alkaline phosphatase In humans a rise in AP levels
may indicate hepatobiliary dysfunction. However,
phosphatase of bone origin must also be taken into
consideration when assessing results. In normal
mice, it has been shown that AP levels are age
related (Figure 4). After treatment with CHIP or
Neoplatin the AP levels were depressed in non-
tumour-bearing mice and remained so throughout
the period of study, (Figure 5). Although tumour-
bearing mice initially had lower levels of AP than
non-tumour-bearing mice, the pattern of change
after CHIP and Neoplatin was similar to that for
untreated mice (Figure 5a).
Isoenzyme studies (Kind unpublished data)
suggest that the alkaline phosphatase was mainly of
bone origin. Whole body autoradiography of
195mPt labelled Neoplatin in non-tumour-bearing
and tumour-bearing mice shows a high persisting
concentration of platinum in cartilage and bone
(Benard et al., 1983). Such a deposition in the non-
tumour-bearing mice may induce damage to the
osteoblasts with a resultant reduction in alkaline
phosphatase activity. In the tumour-bearing mice,
there is a possibility that the bone enzyme may
already be markedly depressed and the enzyme
activity seen after drug treatment may be mainly
that of liver origin which would remain unchanged
provided there was no cholestatic liver involvement.
The depression of AP was noted to be more
marked after Neoplatin in the non-tumour-bearing
animals.770 M. LAVERICK et al.
Serum lipid changes
The marked lipaemia observed after CHIP treat-
ment of tumour-bearing mice was not seen in non-
tumour-bearing mice. This may indicate that the
enzyme, lipoprotein lipase, which is responsible for
the catabolism of circulating triglyceride-rich
lipoproteins (chylomicrons and very low density
lipoprotein), may be suppressed in tumour-bearing
mice, and that this effect is enhanced by CHIP
treatment.
Nephrotoxicity
Nephrotoxicity after Neoplatin therapy is well
recognised in clinical practice and experimental
animals, producing both glomerular and tubular
damage. In their clinical study Campbell et al.
(1983) measured creatinine clearance but in many
rodent studies, the assay of nephrotoxicity is
confined to estimates of blood urea nitrogen (Levi
et al., 1982; Uozomi et al., 1983; Osman et al.,
1984) although Shepherd et al. (1980) also assayed
urinary protein as well. In this study the
biochemical tests used to monitor glomerular
function included both the measurement of serum
urea and creatinine, urinary protein to indicate any
proteinuria present, and urinary NAG activity as a
sensitive indicator of tubular damage.
Serum urea and creatinine The persistently raised
serum urea levels after Neoplatin treatment
confirmed the nephrotoxic effect of this drug
(Figure 6). By contrast, non-tumour-bearing mice
treated with CHIP showed only a transient rise in
serum urea at about Day 45 after treatment.
Harrison et al. (1983) have shown that CHIP has a
greater retention time in the tissues than Neoplatin
and there is a secondary uptake by the kidney,
presumably as a result of the delayed release from
the tissues. The increased serum urea levels on Day
45 in CHIP treated mice may reflect a greater
retention and a subsequent late release of CHIP
from the tissues. It must be pointed out that the
mice in this study received a single dose of CHIP or
Neoplatin albeit at the MTD. The possibility,
therefore, of long term toxicity after repeated drug
administration cannot be ruled out.
In humans a rise in serum urea is usually
accompained by a parallel rise in serum creatinine.
However, no rise in serum creatinine was observed.
It was not practicable to carry out 24h creatinine
clearance studies on the mice as is usually carried
out in human patients for assessment of renal
function. This may have given a better
measurement of glomerular function. Usually as
many as 50% of the functional nephrons will have
to be lost before serum creatinine levels begin to
rise appreciably. The lack of creatinine elevation
may indicate that the raised urea levels may be the
result of an extra renal mechanism such as
increased tissue catabolism or dehydration.
However, we observed neither persistent weight loss
nor signs of dehydration in the treated mice.
Furthermore, in mice, the urine creatinine, creatine
ratio is 1:1 and the metabolism of creatinine and
creatine is probably different from that in humans
where the ratio is 100:1. Therefore, in mice, a rise
in serum creatinine may be a less sensitive indicator
of impaired glomerular function.
Urinaryprotein andNAG The C3H mouse normally
excretes considerable quantities of protein in the
urine. This protein is though to be a 'sex' protein
with the electrophoretic mobility of prealbumin and
a molecular weight of -18,000 daltons (Finlayson
& Baumann, 1958). Most of this protein is filtered
through the glomerulus and it would be expected
that some of the protein would be reabsorbed. The
presence of this sex protein means that changes in
the excretion of other proteins associated with
glomerular and tubular damage may be masked,
only to be identified by more specific immuno-
logical techniques.
No increase in urinary protein excretion was
observed in any of the animal groups to indicate
glomerular or tubular dysfunction. In untreated
tumour-bearing mice, total urinary proteins are
decreased (Kind et al., 1985) and these levels
remained unaltered after treatment with CHIP or
Neoplatin. However when non-tumour-bearing
mice are treated with CHIP or Neoplatin, there was
a marked decrease in protein content, falling to
levels similar to those observed in the untreated
tumour-bearing mice (Figure 7). This decrease in
excretion could again be an indication of a decrease
in protein synthesis.
The reason why the tumour-bearing mice did not
show further reduction in urinary protein levels
after drug treatment is unclear, but may indicate
that the synthesis of the sex protein is the one
mainly affected by the drug treatment and cannot
be suppressed further in mice with already
depressed protein levels. Kind et al. (1985) found
that in fact the total serum proteins were
significantly lower in untreated tumour-bearing
mice and it could be postulated that the sex protein
might also have been affected as well as these
animals.
The fall in urine NAG activity in male mice
treated with CHIP was less apparent than in those
treated with Neoplatin, the level in the mice of the
former group not falling until Day 20. The patterns
were similar but less marked in the females.
However, the tumour-bearing mice showed initiallyBIOCHEMICAL EFFECTS OF CHIP IN MICE 771
increased NAG activity after Neoplatin, indicating
some possible cell damage, (Figure 7). The increase
may have been even greater in the male tumour-
bearing mice as they had some depression of NAG
levels prior to treatment.
The pattern of change for NAG was similar in
most cases to that for urine protein, and this may
be important in the interpretation of results. NAG
activity has been shown to correlate well with
protein levels in normal mouse urine, both being
much higher in males (Kind et al., 1985). The
source of urinary NAG is the lysosomes of the
proximal tubular cells, and that of protein most
likely from the plasma by glomerular filtration. It is
postulated that the load of protein in the proximal
tubule may elicit a lysosomal response for its
reabsorption, hence NAG being released. If urine
protein falls then NAG activity may be reduced.
Therefore the fall in activity seen after CHIP and
Neoplatin in normal mice may be related to both a
decreased protein load and decreased synthesis of
NAG in the kidney. Thus any release of enzyme
due to toxicity may be masked.
It was interesting to observe that in the tumour-
bearing mice there was a rise in NAG activity after
Neoplatin, however there was no change in protein
which might otherwise influence NAG levels? Could
the presence of the tumour make the renal tubular
cells more susceptible to the toxic effects of
Neoplatin?
In conclusion, this study has shown that the pre-
clinical evaluation of the biochemical effects of
cancer chemotherapeutic agents should be under-
taken in tumour-bearing as well as normal animals.
Furthermore, the MTD of the drug should be used
so as to allow a reasonably long period of obser-
vation after treatment. Unexpected renal and
hepatic changes have been revealed which draw
attention to additional mechanisms of drug toxicity
that may occur in clinical practice. The study
confirms that the second generation platinum
coordination complex CHIP is less toxic than the
original complex Neoplatin.
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